Global Anti-Neprilysin Market, By Drug Type (Sacubitril, TD-0714, STR-324, PL-265, and LHW-090), By Indication (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 1,263.3 Mn in 2023, and is expected to exhibit a CAGR of 4.6% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing number of product launches regarding anti-neprilysin drugs is expecetd to drive the global anti-neprilysin market growth over the forecast period. For instance, on January 17, 2023, Glenmark Pharmaceuticals Ltd., a India-based multinational pharmaceutical company, launched the ‘sacubitril + valsartan’ tablets in India, indicated for patients with chronic heart failure. Marketed under the brand name ‘Sacu VTM’, it must be taken twice under a doctor’s prescription.
Global Anti-Neprilysin Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019,as "coronavirus disease 2019" or COVID-19. This virus spreads, quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others, faced problems with regard to the transportation of drugs from one place to another.
The COVID-19 pandemic significantly augmented demand for several drugs. The spread of coronaviruses also negatively impacted the sales of companies whose product demand highly depends on selective disease treatments such as anti-neprilysin that areused for the treatment of heart diseases. Furthermore, patients with cardiovascular disease were highly at risk of being affected by the COVID-19 infection due to fragile heart conditions. The COVID-19 virus infects the lungs and drops blood oxygen levels at first, and secondly, the inflammatory effects of the virus itself will cause the blood pressure to drop. In such cases, the heart must beat faster to supply oxygen to major organs, due to which the survival rates of individuals with ailing heart conditions become very low, even with proper medications.
Global Anti-Neprilysin Market : Key Developments
Strategies like partnerships and agreements can help the product reach more regions. This is expected to boost market growth during the forecast period.
For instance, in February 2020, Otsuka Pharmaceutical Co., Ltd., a holistic healthcare company, and Novartis AG, a Switzerland-based global healthcare company, signed a co-promotion agreement in Japan for Novartis AG's angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 (generic name: sacubitril valsartan sodium hydrate), currently being developed by Novartis AG as a planned treatment for chronic heart failure. Under the terms of this agreement, Novartis AG and Otsuka Pharmaceutical Co., Ltd. will jointly undertake the promotion of LCZ696 to healthcare practitioners in Japan. LCZ696 is a new type of drug that reduces cardiac load in chronic heart failure by activating a protective neurohormonal mechanism (the natriuretic peptide system) while suppressing the harmful effects of overactivity of the renin-angiotensin-aldosterone system (RAAS).
Browse 34 Market Data Tables and 36 Figures spread through 168 Pages and in-depth TOC on “Global Anti-Neprilysin Market”- Forecast to 2030, Anti-Neprilysin Market, by Drug Type (Sacubitril, TD-0714, STR-324, PL-265, and LHW-090), by Indication (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer’s Disease, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/anti-neprilysin-market-4164
Key Takeaways of the Global Anti-Neprilysin Market:
- The global anti-neprilysin market is expected to exhibit a CAGR of 4.6% during the forecast period due to the increased research and development activities regarding anti-neprilysin drugs across the globe. According to an article published in December 2020 by John Wiley & Sons, Inc., a U.S.-based multinational publishing company, subtypes of hypertension can also benefit from sacubitril or valsartan.
- Among drug type, Sacubitril segment is expected to grow in the global anti-neprilysin market over the forecast period. According to an article published in April 2022, by PubMed, a free search engine for biological databases and medical reports, scubitril/valsartan combination significantly reduced office and ambulatory BP in refractory hypertension patients belonging to Asia.
- Among regions, North America is expected to be the dominant region in the global anti-neprilysin market, owing to the increasing research activities in this region. According to a data shared on June 6, 2023, by the Journal of the American College of Cardiology, a peer-reviewed medical journal covering all aspects of cardiovascular disease, in patients with ejection fraction (EF) greater than 40% who were stabilized after a worsening heart failure (WHF) event, sacubitril/valsartan (sac/val) led to a greater reduction in plasma N-terminal proBNP levels.
- Major players operating in the global anti-neprilysin market include BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd.
